• » Corporate
• Letter from the CEO
• Company Fact Sheet
• Quality Policy and Objectives
• » Leadership
• Peter Lea, Ph.D.
• Claude Ricks
• Andrew Morris, M.Sc., MBA
• Thomas E.T. O'Connor
• Kate Smith
• Sasi Mudumba, Ph.D.
• Denis Bosc, Ph.D.
• Darryl Burke
• Geihan Rizkalla, M.Sc., CQM
• » Board of Directors
• » Investors
• » News & Media
• Press Releases 2010
• Press Releases 2009
• Press Releases 2008
• » Career Openings
• » Contact Us

Press Releases

SQI Diagnostics Ships Automated Multi-Biomarker SQiDworks™ Platform to the Cleveland Clinic for Validation Trials

Released: Feb 19, 2008

Toronto, Ontario, January 18th, 2008– SQI Diagnostics Inc. (TSX-V: SQD), a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced that it has shipped its automated SQiDworks™ platform to the Cleveland Clinic in Cleveland, Ohio. The Cleveland Clinic laboratory is the second external validation partner to receive the platform and will evaluate its analytic performance along with SQI Diagnostics' QuantiSpot™ RA assay, generating data to be used by SQI Diagnostics for regulatory submissions.

"Having our platform undergo validation trials by one of the leading hospitals in the US is a significant achievement for SQI Diagnostics and demonstrates the desire these hospitals have for a breakthrough technology that could save them time and money when conducting high volume multiple biomarker tests," said Claude Ricks, CEO of SQI Diagnostics. "We anticipate completing this validation trial in the first half of 2008 and intend to submit these results to support our regulatory filings shortly thereafter."

The data from the validation trials being conducted at Mount Sinai Hospital (Toronto) and the Cleveland Clinic (Cleveland Ohio), together with internal validation trial data, will be used to seek regulatory clearance for the automated SQiDworks Platform and the Company’s lead QuantiSpot microarray panel for rheumatoid arthritis (QuantiSpot RA). SQI Diagnostics continues to develop its menu of QuantiSpot assays for autoimmune diseases and plans to initiate validation trials for its second multiplex assay for antiphospholipid syndrome, (APS) biomarkers in 2008.

About SQiDworks
SQiDworks is a fully-automated fluidics workstation, scanner and analytical device used to process SQI Diagnostics proprietary QuantiSpot microarray test devices. The platform fully integrates all assay steps for hands-free work-flow and is compatible with standard lab automation systems. The platform is capable of processing up to 240 patient samples per run and when combined with the Company's QuantiSpot multiplexed tests can produce quantified determinations for up to 960 individual test results per hour resulting in significant laboratory efficiencies and cost-savings.

About QuantiSpot
The SQI Diagnostics microarray device, QuantiSpot, is a multiplexed assay consumable for use with the SQiDworks workstation. QuantiSpot tests are currently being developed for the detection and quantification of biomarkers used in the diagnosis of Autoimmune Disease, Infectious Disease and Allergic conditions, among others. Each of the 96 wells of the QuantiSpot device contains proprietary microarrays for duplicate antibody capture, in-sample calibration and redundant test controls. When combined with the SQiDworks fully-automated workstation, users are able to process multiplexed assays to quantify serum concentrations of up to 12 individual biomarkers or the qualitative detection of up to 24 biomarkers per patient.

About SQI Diagnostics
SQI Diagnostics is a medical systems automation company focused on evolving laboratory-based biomarker testing. Using automation and proprietary miniaturization technologies, SQI Diagnostics significantly improves the economies of scale for laboratories performing multiple biomarker testing at high volumes, allowing them to deliver patient results faster using less labour and fewer resources. SQI Diagnostics' platform has a user-friendly interface, high sample throughput and offers a more efficient alternative to current testing options. SQI Diagnostics' initial products target the $1.4 billion autoimmune disease market, with initial products for rheumatoid arthritis and thrombosis scheduled for launch in 2008. SQI Diagnostics is based in Toronto, Canada. For further information please visit www.sqidiagnostics.com.

For further information please contact:

Certain information in this press release is based on beliefs and assumptions of the Company's senior management and information currently available to it that may constitute forward-looking information within the meaning of securities laws. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements.

This release was prepared by management of the Company who takes full responsibility for its contents. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.